People · Operator

Richard C Wagner

Named in public records as an officer, director or promoter · active 2015–2019 · Other Technology, Pharma

2
Companies
3
Filings
$54.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Prevedere, Inc.Other TechnologySeries B$44.7M$300.4M2015
ZebiAI Therapeutics, Inc.PharmaSeries A$10.0M$309.7M2019
Operator network

Richard C Wagner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Promod Haque · 13 companies · 1 sharedPromod HaqueKrish Panu · 6 companies · 1 sharedKrish PanuPeter Thomas · 3 companies · 1 sharedPeter ThomasDaniel Fishback · 2 companies · 1 sharedDaniel FishbackKen Coleman · 2 companies · 1 sharedKen ColemanPromod C. Haque · 2 companies · 1 sharedPromod C. HaqueRichard Wagner · 2 companies · 1 sharedRichard WagnerDaniel C Fishback · 1 companies · 1 sharedDaniel C FishbackDon C Fowler · 1 companies · 1 sharedDon C FowlerDon Fowler · 1 companies · 1 sharedDon FowlerKen C Coleman · 1 companies · 1 sharedKen C ColemanPeter C Thomas · 1 companies · 1 sharedPeter C ThomasBrant C. Binder · 1 companies · 1 sharedBrant C. BinderPhilip C. Austin · 1 companies · 1 sharedPhilip C. AustinPrevedere, Inc. · $44.7M raisedPrevedere, Inc.ZebiAI Therapeutics, Inc. · $10.0M raisedZebiAI Therapeutics, …Richard C WagnerRW
Richard C Wagner Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Richard C Wagner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Promod Haque113
Krish Panu16
Peter Thomas13
Promod C. Haque12
Richard Wagner12
Ken Coleman12
Daniel Fishback12
Philip C. Austin11
Don Fowler11
Ken C Coleman11
Peter C Thomas11
Don C Fowler11
Daniel C Fishback11
Brant C. Binder11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.